There are 3164 resources available
1926MO - Radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients treated with lenvatinib monotherapy: Real-world treatment patterns and clinical outcomes in Europe and Canada
Presenter: Laura Locati
Session: Mini oral session: NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
Fertility preservation and beyond in female patients with cancer
Presenter: Matteo Lambertini
Session: Oncofertility: What every HCP involved in cancer care should know
Resources:
Slides
Webcast
Multi-cancer early detection tests: Caveats and future potential
Presenter: Charles Swanton
Session: The dark age of single cancer screening is over
Resources:
Slides
Webcast
DC stratification survey
Presenter: Jayne Wood
Session: 9th ESMO Designated Centres of Integrated Oncology and Palliative Care session and awards: Specific considerations for integration of oncology and palliative care
Resources:
Slides
Webcast
Treatments for eTNBC patients with non-pCR after chemo-immunotherapy
Presenter: Joana Ribeiro
Session: The rapidly changing treatment landscape of early triple negative breast cancer
Resources:
Slides
Webcast
Could optimal systemic therapy be adequate without locoregional therapy?
Presenter: Srikala Sridhar
Session: Can we expand bladder preservation by optimal use of systemic therapy and biomarkers?
Resources:
Slides
Webcast
The current state-of-the-art in lung cancer screening
Presenter: Torsten Blum
Session: Lung cancer interception: New approaches to lung cancer screening and prevention
Resources:
Slides
Webcast
Harnessing the immune system as a therapeutic tool in the treatment of head and neck cancers
Presenter: Kirsten Lauber
Session: Personalised immunotherapy strategies for head and neck cancers
Resources:
Slides
Webcast
VP5-2023: Primary results from BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase III trial of first-line atezolizumab (atezo) combined with a platinum doublet and bevacizumab (bev) for metastatic (stage IVB), persistent or recurrent cervical cancer (R/M CC)
Presenter: Leslie Randall
Session: ESMO Virtual Plenary revisited
Resources:
Slides
Webcast
1721MO - Safety and efficacy of olutasidenib, an IDH1 mutant inhibitor, for the treatment of recurrent/relapsed or locally advanced or metastatic IDH1 mutated chondrosarcoma
Presenter: Florence Duffaud
Session: Mini oral session: Sarcoma
Resources:
Abstract
Slides
Webcast